Novel therapies for osteoporosis.

@article{Makras2015NovelTF,
  title={Novel therapies for osteoporosis.},
  author={Polyzois Makras and Sideris P Delaroudis and Athanasios D Anastasilakis},
  journal={Metabolism: clinical and experimental},
  year={2015},
  volume={64 10},
  pages={1199-214}
}
Since the identification of osteoporosis as a major health issue in aging populations and the subsequent development of the first treatment modalities for its management, considerable progress has been made in our understanding of the mechanisms controlling bone turnover and disease pathophysiology, thus enabling the pinpointing of new targets for intervention. This progress, along with advances in biotechnology, has rendered possible the development of ever more sophisticated treatments… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

The effect of cathepsin K inhibitor surface treatment on delayed tooth replantation in dogs.

Dental traumatology : official publication of International Association for Dental Traumatology • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 135 references

Findings from denosumab (Prolia®) post-marketing safety surveillance for atypical femoral fracture, osteonecrosis of the jaw, severe symptomatic hypocalcemia, and anaphylaxis

M Geller, RB Wagman, +3 authors NB Watts
J Bone Miner Res • 2014
View 4 Excerpts
Highly Influenced

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2010
View 12 Excerpts
Highly Influenced

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2009
View 5 Excerpts
Highly Influenced

Denosumab for the treatment of osteoporosis.

Expert opinion on drug metabolism & toxicology • 2015
View 4 Excerpts
Highly Influenced

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2004
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…